Free tool
FAERS Monitor: Tyruko
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761322 or its brand name (Tyruko, Natalizumab-Sztn). Reports on generic versions are filed under their own applications.
Reports
237
Serious
217
92% of reports
Hospitalization
28
Death reported
4
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- fatigue73
- mobility decreased53
- balance disorder31
- headache22
- product substitution issue21
- muscular weakness17
- multiple sclerosis relapse16
- cognitive disorder14
- gait disturbance13
- progressive multifocal leukoencephalopathy13
- dizziness12
- nausea12
- urinary incontinence11
- multiple sclerosis9
- rash9
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2024 | 110 |
| 2025 | 92 |
| 2026 | 35 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,922 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| progressive multifocal leukoencephalopathySignal | 13 | 140.1 | 82.6 | 1,657 |
| mobility decreasedSignal | 53 | 65.5 | 51.7 | 3,312 |
| urinary incontinenceSignal | 11 | 33.0 | 18.5 | 310 |
| product substitution issueSignal | 21 | 32.4 | 21.5 | 609 |
| balance disorderSignal | 31 | 31.8 | 22.9 | 899 |
| cognitive disorderSignal | 14 | 26.6 | 16.0 | 321 |
| multiple sclerosis relapseSignal | 16 | 20.7 | 12.9 | 282 |
| multiple sclerosisSignal | 9 | 16.7 | 8.8 | 118 |
| muscular weaknessSignal | 17 | 13.3 | 8.4 | 182 |
| fatigueSignal | 73 | 8.3 | 6.9 | 481 |
| gait disturbanceSignal | 13 | 6.0 | 3.6 | 50 |
| headacheSignal | 22 | 3.1 | 2.1 | 30 |
| dizzinessSignal | 12 | 2.1 | 1.2 | 6 |
| rash | 9 | 1.8 | 1.0 | 3 |
| nausea | 12 | 1.3 | 0.8 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.